<DOC>
	<DOCNO>NCT00125346</DOCNO>
	<brief_summary>Lung infection chronic problem patient cystic fibrosis ( CF ) . Some patient CF may type bacteria call Pseudomonas aeruginosa lung cause infection make symptoms bad . Tobramycin inhalation solution ( TOBI ) approve antibiotic , inhale directly lung , use manage infection . Tobramycin inhalation powder ( TIP ) new , experimental powder formulation tobramycin inhale directly lung use T-326 inhaler . The purpose research study determine TIP safe effective compare placebo ( powder medicine ) treatment .</brief_summary>
	<brief_title>Tobramycin Inhalation Powder ( TIP ) Cystic Fibrosis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Confirmed diagnosis cystic fibrosis patient Pseudomonas aeruginosa infection . Male female subject 6 21 year age time screen . FEV1 screen must 25 % 80 % normal predict value . Known local systemic hypersensitivity aminoglycosides inhale antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Tobramycin Inhalation Powder</keyword>
</DOC>